These findings suggest that CDC25B level may be a marker of or contribute to BET inhibitor sensitivity in this tumor type, and that JQ1 sensitizes gemR cells to CDC25 inhibitors and to gemcitabine. The gene discussed is CDC25B; the disease is neoplasm.